AARD
AARD
US0029421007
Aardvark Therapeutics, Inc.
Loading chart...

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Latest News

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
AARDALMS
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AARD
AARD
AARD
AARD

Related stocks

ALT
ALT • United States
Altimmune, Inc.
2.61 USD
507.69M USD 1Y -33.8%
ALLO
ALLO • United States
Allogene Therapeutics, Inc.
1.46 USD
504.42M USD 1Y -4.8%
CTNM
CTNM • United States
Contineum Therapeutics, Inc.
13.38 USD
503.37M USD 1Y +8.4%
PBYI
PBYI • United States
Puma Biotechnology Inc
10.29 USD
531.17M USD 1Y +90.6%
MNPR
MNPR • United States
Monopar Therapeutics Inc.
78.96 USD
529.99M USD 1Y -14.8%
NGNE
NGNE • United States
Neurogene Inc.
26.4 USD
528.3M USD 1Y +2.6%
DRUG.CN
DRUG.CN • United States
BrightMindsBio
77.1 CAD
533.55M USD 1Y -10.3%
RGNX
RGNX • United States
REGENXBIO Inc.
8.07 USD
532.73M USD 1Y -33.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology
Website
https://aardvarktherapeutics.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
-
Max Drawdown (3Y)
-
Sharpe Ratio (3Y)
-
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
ende